Anticoagulants in Seniors With A-Fib, CKD Ups Stroke, ICH RiskLast Updated: February 20, 2018. For older patients with concomitant chronic kidney disease and a new diagnosis of atrial fibrillation, anticoagulants are associated with increased risk of ischemic stroke and hemorrhage, but with reduced risk of all-cause mortality, according to a study published online Feb. 14 in The BMJ.
TUESDAY, Feb. 20, 2018 (HealthDay News) -- For older patients with concomitant chronic kidney disease and a new diagnosis of atrial fibrillation, anticoagulants are associated with increased risk of ischemic stroke and hemorrhage, but with reduced risk of all-cause mortality, according to a study published online Feb. 14 in The BMJ.
Shankar Kumar, M.B.B.S., from University College London, and colleagues conducted a propensity-matched population-based cohort analysis from January 2006 through December 2016. Participants were aged 65 years and older with a new diagnosis of atrial fibrillation and estimated glomerular filtration rate of <50 mL/min/1.73 m². Using propensity-score matching, 2,434 pairs of patients who were and were not on anticoagulants within 60 days of diagnosis were included.
The researchers found that the crude rates for ischemic stroke and hemorrhage were 4.6 and 1.2 per 100 person-years after taking anticoagulants and 1.5 and 0.4 in patients not taking anticoagulants. Compared to those who received no anticoagulation, the hazard ratios for ischemic stroke, hemorrhage, and all-cause mortality were 2.60, 2.42, and 0.82, respectively, for those on anticoagulants.
"Giving anticoagulants to older people with concomitant atrial fibrillation and chronic kidney disease was associated with an increased rate of ischemic stroke and hemorrhage but a paradoxical lowered rate of all-cause mortality," the authors write. "Careful consideration should be given before starting anticoagulants in older people with chronic kidney disease who develop atrial fibrillation."
|Previous: Hydroxychloroquine No Better Than Placebo for Hand OA||Next: AAD: Ustekinumab Cuts Vascular Inflammation in Psoriasis|
Reader comments on this article are listed below. Review our comments policy.